AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- $0No open-market trades
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 0 added, 9 cutMore cutting
Market overview
Fundamentals Jun 30- 52-wk high
- $40.56
- 52-wk low
- $13.20
- Mkt cap
- $6.27B
- Beta
- 1.12
- Div yield
- 93.80%
- P/S
- 409.2x
- P/B
- 12.9x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -57.4%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CNTA filings
Are insiders buying or selling Centessa Pharmaceuticals PLC ADR (CNTA) stock?
Neither. Centessa Pharmaceuticals PLC ADR (CNTA) insiders filed no open-market purchases or sales in the 90 days to Oct 12, 2026, according to SEC Form 4 filings.
Which members of Congress have traded CNTA recently?
None. No member of Congress disclosed a CNTA trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CNTA smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Sells/Trims (3)
- FC
Farallon Capital
$191.0M
sold
- MC
Maverick Capital
$73.7M
sold
- BO
Bank of America
$76.8M
sold
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CNTA right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Results versus expectations
No earnings history.
What the street expects next
Financials
Is the business strong?
This company is running thin margins.
- Net margin
- 0.0%
- Market cap
- $6.3B
Valuation
- P/S409.21
- P/B12.86
- Dividend yield93.8%
Quality
- Operating margin0.0%
- ROE-57.4%
- ROA-27.4%
Growth
- Beta1.12
Technicals
Price structure
Market data unavailable.